The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

At Novartis, we believe in the importance of balancing professional and personal responsibilities. This belief is embodied through our inclusive parental leave policy, which supports all our people in ...

ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Kymriah (tisagenlecleucel) is a prescription drug that’s used to treat certain types of leukemia and lymphoma. The drug is given as an intravenous (IV) infusion. Kymriah is usually given as a ...

Chimeric antigen receptor-engineered T cell therapies (CAR-T) are becoming powerful immunotherapeutic tools for treating malignancies, especially hematological malignancies. Like other biological ...

This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...

Novartis’ Fabhalta is the only Factor B inhibitor approved in the country. Credit: JHVEPhoto/Shutterstock. Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral ...

12,13 Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are ...

Sorry, there were no product categories that matched your search term. To improve our service and ensure this does not happen in the future, please take a moment to ...

and Novartis' Kymriah (tisagenlecleucel). And in 2024, Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel) became a new competitor to Kite's Tecartus (brexucabtagene autoleucel) in the relapsed ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost ...